Head-to-head · Cost-Efficiency Index
TRT Kingdom vs VivioMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
TRT Kingdom
Shoppers open to a TRT-focused telehealth brand's GLP-1 line who are comfortable committing to a 4-month prepay term for the advertised rate.
Visit TRT KingdomVivioMD
Shoppers who want both compounded and FDA-approved GLP-1 options from one nationwide platform, and don't mind completing an intake before seeing price.
Visit VivioMDThe verdict
TRT Kingdom takes it, leading the Cost-Efficiency Index 54 to 53. TRT Kingdom -- despite its testosterone-focused name -- runs a genuine compounded GLP-1 weight-loss line ('Compounded GLP-1' and 'Compounded GLP-1/GIP') priced at $149/month and $199/month respectively. VivioMD still earns a C — Shoppers who want both compounded and FDA-approved GLP-1 options from one nationwide platform, and don't mind completing an intake before seeing price.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs TRT Kingdom.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | TRT Kingdom | VivioMD |
|---|---|---|
| Cost-Efficiency Index | 54/100 | 53/100 |
| Semaglutide / mo | $149/mo (compounded) | Not disclosed |
| Tirzepatide / mo | $199/mo (compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $1,788 | — |
| Tirzepatide / yr (modeled) | $2,388 | — |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #365 | #369 |
TRT Kingdom
54/100Where the value is
- Confirmed, real compounded GLP-1 (semaglutide) and GLP-1/GIP (tirzepatide) products exist and are separately priced, despite the company's TRT-focused branding
- Named clinical group and Chief Medical Officer (REM Health Medical Group, P.A.; Daniel Olivero) plus two named nurse practitioners
- LegitScript verification badge displayed
The tradeoffs
- The advertised $149/$199 monthly rates require committing to a 4-month plan; no month-to-month or shorter-term price is published
- Pharmacy is described only as 'an FDA registered pharmacy in the USA' -- no name, state, or accreditation given
VivioMD
53/100Where the value is
- Offers both compounded AND FDA-approved branded GLP-1s (Ozempic, Zepbound) -- more flexibility than compounded-only competitors
- Four named pharmacy partners disclosed by name, more transparency than most peers
- Broad state coverage -- 49 states, only Louisiana excluded
The tradeoffs
- No pricing whatsoever is published -- every price is gated behind a full intake assessment
- No medical director name disclosed anywhere on the accessible pages
Regulatory note: the FDA issued a warning letter to VivioMD Group LLC dba VivioMD in June 2026. We still list and link to VivioMD; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.